Sulfamides as novel histone deacetylase inhibitors.

The sulfamide moiety has been utilized to design novel HDAC inhibitors. The potency and selectivity of these inhibitors were influenced both by the nature of the scaffold, and the capping group. Linear long-chain-based analogs were primarily HDAC6-selective, while analogs based on the lysine scaffold resulted in potent HDAC1 and HDAC6 inhibitors.

[1]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[2]  Christine G. Espino,et al.  Synthesis of 1,3-Difunctionalized Amine Derivatives through Selective C−H Bond Oxidation , 2001 .

[3]  R. De Francesco,et al.  Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Michael Rowley,et al.  A series of novel, potent, and selective histone deacetylase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[5]  A. C. Krueger,et al.  Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-alkyl-4-hydroxyquinolon-3-yl-benzothiadiazine sulfamides. , 2006, Bioorganic & medicinal chemistry letters.

[6]  Takayoshi Suzuki,et al.  Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design. , 2005, Bioorganic & medicinal chemistry letters.

[7]  R. De Francesco,et al.  A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. , 2008, Journal of medicinal chemistry.

[8]  S. Horinouchi,et al.  Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase , 1999, Oncogene.

[9]  A. Kalita,et al.  (2-Amino-phenyl)-amides of ω-substituted alkanoic acids as new histone deacetylase inhibitors , 2004 .

[10]  Sylvain Lefebvre,et al.  MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo , 2008, Molecular Cancer Therapeutics.

[11]  P. Finn,et al.  Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. , 2003, Molecular cancer therapeutics.

[12]  M. K. Pflum,et al.  Isoform-selective histone deacetylase inhibitors. , 2008, Chemical Society reviews.

[13]  Yukihiro Itoh,et al.  Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. , 2007, Journal of medicinal chemistry.

[14]  Andreas Schwienhorst,et al.  Histone deacetylases—an important class of cellular regulators with a variety of functions , 2007, Applied Microbiology and Biotechnology.

[15]  S. Campbell,et al.  Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists. , 1990, Journal of medicinal chemistry.

[16]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[17]  Stuart L Schreiber,et al.  Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. McComsey,et al.  Carbonic anhydrase-II inhibition. what are the true enzyme-inhibitory properties of the sulfamide cognate of topiramate? , 2008, Journal of medicinal chemistry.

[19]  D. Faller,et al.  Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? , 2003, Current cancer drug targets.

[20]  M. Binaschi,et al.  Histone deacetylase inhibitors: from bench to clinic. , 2008, Journal of medicinal chemistry.

[21]  Therapeutic potential of sulfamides as enzyme inhibitors , 2006, Medicinal research reviews.

[22]  C. Supuran,et al.  Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. , 2006, Journal of medicinal chemistry.

[23]  C. Maroun,et al.  Histone deacetylase inhibitors: latest developments, trends and prospects. , 2005, Current medicinal chemistry. Anti-cancer agents.

[24]  M. Janicot,et al.  HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry,Biology and Clinical Benefit , 2007 .

[25]  P. Atadja,et al.  The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. , 2006, Cancer research.

[26]  A. Ho,et al.  Chromosomal organization and localization of the novel class IV human histone deacetylase 11 gene. , 2005, International journal of molecular medicine.

[27]  J. R. Somoza,et al.  Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. , 2004, Structure.

[28]  P. Devillier,et al.  New calcium antagonists: synthesis, X-ray analysis, and smooth muscle relaxing effect of 3-[O-(benzyl-substituted)-oximino-ethers]-hexahydroazepin-2,3- diones. , 1999, Bioorganic & medicinal chemistry.

[29]  Andrea Scozzafava,et al.  Carbonic anhydrase inhibitors: inhibition of cytosolic isozymes I and II with sulfamide derivatives. , 2003, Bioorganic & medicinal chemistry letters.

[30]  Ø. Bruserud,et al.  Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells , 2007 .

[31]  Keith B Glaser,et al.  Trifluoromethyl ketones as inhibitors of histone deacetylase. , 2002, Bioorganic & medicinal chemistry letters.

[32]  A. Kohara,et al.  Thiol-based SAHA analogues as potent histone deacetylase inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[33]  M. Jung,et al.  Analogues of trichosтatin a and trapoxin B as histone deacetylase inhibitors , 1997 .

[34]  D M Schmatz,et al.  Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Isabelle Paquin,et al.  Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. , 2008, Journal of medicinal chemistry.